Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIVOLUMAB Cause Incorrect product administration duration? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Incorrect product administration duration have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.0% of all adverse event reports for NIVOLUMAB.

9
Reports of Incorrect product administration duration with NIVOLUMAB
0.0%
of all NIVOLUMAB reports
0
Deaths
3
Hospitalizations

How Dangerous Is Incorrect product administration duration From NIVOLUMAB?

Of the 9 reports, 3 (33.3%) required hospitalization, and 2 (22.2%) were considered life-threatening.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does NIVOLUMAB Cause?

Death (11,216) Malignant neoplasm progression (9,363) Off label use (5,208) Diarrhoea (4,692) Fatigue (3,709) Pyrexia (3,454) Intentional product use issue (3,297) Rash (2,816) Nausea (2,805) Decreased appetite (2,619)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which NIVOLUMAB Alternatives Have Lower Incorrect product administration duration Risk?

NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW NIVOLUMAB vs NIZATIDINE NIVOLUMAB vs NOMEGESTROL NIVOLUMAB vs NORDAZEPAM NIVOLUMAB vs NOREPINEPHRINE

Related Pages

NIVOLUMAB Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration NIVOLUMAB Demographics